Liver fibrosis progression in hepatitis C virus infection after seroconversion.
暂无分享,去创建一个
D. Leaf | A. Justice | D. Rimland | M. Freiberg | M. Goetz | A. Butt | K. Sherman | M. Klein | V. Lo Re | P. Yan
[1] G. Dusheiko,et al. Natural history of hepatitis C. , 2014, Journal of hepatology.
[2] S. Wild,et al. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. , 2014, Journal of hepatology.
[3] M. Vinciguerra,et al. Sympathetic Nervous System Catecholamines and Neuropeptide Y Neurotransmitters Are Upregulated in Human NAFLD and Modulate the Fibrogenic Function of Hepatic Stellate Cells , 2013, PloS one.
[4] A. Moorman,et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] M. Freiberg,et al. Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co‐infection and baseline anaemia , 2013, Journal of viral hepatitis.
[6] M. Freiberg,et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] Farah Kidwai,et al. Validity of diagnostic codes and liver‐related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study , 2011, Pharmacoepidemiology and drug safety.
[8] L. Fried,et al. HCV infection and the incidence of CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] E. Ridruejo. Hepatitis C treatment completion rates in routine clinical care , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[10] A. Butt,et al. Effect of hepatitis C virus and its treatment on survival , 2009, Hepatology.
[11] J. Tsevat,et al. Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers , 2009 .
[12] M. Budoff,et al. Hepatitis C virus infection and the risk of coronary disease. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] C. Chang,et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis , 2007, Journal of viral hepatitis.
[14] A. Butt,et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. , 2007, Journal of viral hepatitis.
[15] Melissa Skanderson,et al. Development and Verification of a “Virtual” Cohort Using the National VA Health Information System , 2006, Medical care.
[16] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[17] A. Justice,et al. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans , 2005, AIDS.
[18] H. El‐Serag,et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. , 2005, Journal of hepatology.
[19] C. Kwoh,et al. Risk of diabetes in HIV infected veterans pre‐ and post‐HAART and the role of HCV coinfection , 2004, Hepatology.
[20] J. Crowe,et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection , 2001, Gut.
[21] L. Seeff,et al. Natural history of hepatitis C , 1997, Hepatology.
[22] M. Leal,et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. , 1997, Journal of hepatology.
[23] M. Tong,et al. Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.
[24] O. Weiland,et al. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. , 2008, Liver.
[25] Richard E. Sampliner,et al. The Natural History of Community-Acquired Hepatitis C in the United States , 1993 .
[26] R. Koretz,et al. Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade , 1993, Annals of Internal Medicine.
[27] A. Alberti,et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1993, Journal of hepatology.
[28] K. Ishak,et al. Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.
[29] R. Purcell,et al. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.
[30] H. Blum,et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). , 1990, Journal of hepatology.
[31] R. W. Mccollum. The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.